Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors

被引：0
|
作者：
Guimaraes-Young, Amy [1 ]
Davies, Kurtis D. [1 ]
Trevisan, Patricia [1 ]
Nijmeh, Hala [1 ]
Haag, Mary [1 ]
Aisner, Dara L. [1 ]
Patil, Tejas [2 ]
机构：
[1] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA
[2] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA
来源：
JCO PRECISION ONCOLOGY | 2024年 / 8卷
关键词：
KIF5B-EGFR FUSION;
D O I：
10.1200/PO-24-00526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
    Zhao, Yiming
    Wang, Shuyuan
    Zhang, Bo
    Qiao, Rong
    Xu, Jianlin
    Zhang, Lele
    Zhang, Yanwei
    Han, Baohui
    TARGETED ONCOLOGY, 2019, 14 (02) : 169 - 178
  • [32] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
    Yiming Zhao
    Shuyuan Wang
    Bo Zhang
    Rong Qiao
    Jianlin Xu
    Lele Zhang
    Yanwei Zhang
    Baohui Han
    Targeted Oncology, 2019, 14 : 169 - 178
  • [33] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [34] Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
    Chen, K.
    Yu, X.
    Wang, H.
    Huang, Z.
    Xu, Y.
    Gong, L.
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1736 - S1737
  • [35] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
    Jassem, Jacek
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
  • [36] The Efficacy of EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring G719X Mutation
    Wang, H.
    Zhang, L.
    Lu, T.
    Zhang, X.
    Si, X.
    Wang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2146
  • [37] Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
    Ma, Chunhua
    Zhang, Juncheng
    Tang, Dongjiang
    Ye, Xin
    Li, Jing
    Mu, Ning
    Li, Zhi
    Liu, Renzhong
    Xiang, Liang
    Huang, Chuoji
    Jiang, Rong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [38] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    LUNG CANCER, 2021, 156 : S40 - S40
  • [39] Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
    Heigener, David F.
    Schumann, Christian
    Sebastian, Martin
    Sadjadian, Parvis
    Stehle, Ingo
    Maerten, Angela
    Lueers, Anne
    Griesinger, Frank
    Scheffler, Matthias
    ONCOLOGIST, 2015, 20 (10): : 1167 - 1174
  • [40] A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Gawli, Chandrakant S.
    Patil, Chandragouda R.
    Patel, Harun M.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 123
12345